Screening for Residual Disease in Pediatric Burkitt Lymphoma Using Consensus Primer Pools
Table 1
Persistent
or minimal residual disease assessment using real-time and PSP assays.
Case (Dx)
Real-time
results/PSP results & clinical status*
Entry
1 Mo
2
Mo
3-4 Mo
Clinical status
NHL-1 (BL)
Tissue (+/PSP)
CR
(End of Rx))
Blood (+/+)
Blood (−/−)
Blood
(+/+)
Blood (−/−)
NHL-2 (BL)
Tissue (+/PSP)
CR
(End of Rx)
Blood (+/+)
Blood (+/+)
Blood (−/−)
BMA (+/+)
NHL-3
(BL)
Tissue (+/PSP)
Dead (Infection; 3 mo)
Blood (+/+)
Blood (+/+)
BMA (+/+)
BMA (−/−)
NHL-4 (BL)
Tissue (+/PSP)
CR ( End of Rx )
Blood (+/+)
Blood (+/+)
Blood (−/−)
NHL-5 (BL)
Tissue (+/PSP)
BMA relapse (6 mo)
Blood (+/+)
Blood (−/−)
BMA (+/+)
BMA (+/+)
NHL-6 (BL)
Tissue (+/PSP)
CR ( End of Rx )
BMA (+/+)
BMA (−/−)
NHL-7
(BL)
Tissue (+/PSP)
BMA relapse (3 mo)
BMA (+/+)
BMA (+/+)
NHL-8
(BL)
Tissue (+/PSP)
Blood (+/+)
Blood (−/−)
Blood (−/−)
CR (End of Rx)
NHL-9 (BL)
Tissue (+/PSP)
Blood (+/+)
Blood (+/+)
Blood (−/−)
CR (End of Rx)
CSF (+/+)
CSF (=/=)
NHL-10 (BL)
Tissue (+/PSP)
Blood (+/+)
Blood (−/−)
CR (End of Rx)
NHL-11 (BL)
Tissue (+/PSP)
Blood (+/+)
Blood (+/+)
Blood (+/+)
Blood (−/−)
CR (End of Rx)
NHL-12 (BL)
Tissue (+/PSP)
Blood (+/+)
Blood (+/+)
Blood (−/−)
CR (End of Rx)
BMA (Equiv)
BMA (+/+)
BMA (−/−)
CSF (+/+)
NHL-13
(BL)
Tissue (+/PSP)
Blood (+/+)
Blood (=/=)
Blood (=/=)
BMA (+/+)
BMA(−/−)
CR (End of Rx)
CSF(−/−)
NHL-14 (BL)
Tissue (+/PSP)
Blood (+/+)
Blood (−/−)
Blood (−/−)
CR (End of Rx)
BMA (+/+)
Specimens were not available from some time points;
Dx: diagnosis; BL: Burkitt lymphoma; BMA: bone marrow aspirate; real-time
results/patient-specific primer (PSPs) results: Positive (+), Negative (−), or Equivocal (=) for each assay result; CR: complete remission; End of Rx: End of
therapy.
